KR20230067646A - 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 - Google Patents

리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 Download PDF

Info

Publication number
KR20230067646A
KR20230067646A KR1020237012412A KR20237012412A KR20230067646A KR 20230067646 A KR20230067646 A KR 20230067646A KR 1020237012412 A KR1020237012412 A KR 1020237012412A KR 20237012412 A KR20237012412 A KR 20237012412A KR 20230067646 A KR20230067646 A KR 20230067646A
Authority
KR
South Korea
Prior art keywords
salt
week
oxo
sulfamoyl
dimethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012412A
Other languages
English (en)
Korean (ko)
Inventor
히로유키 우에노
다쿠야 호시노
해롤드 키어
아람 오가네샨
Original Assignee
다이호야쿠힌고교 가부시키가이샤
아스텍스 파마수티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤, 아스텍스 파마수티컬스, 인크. filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20230067646A publication Critical patent/KR20230067646A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237012412A 2020-09-15 2021-09-15 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 Pending KR20230067646A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078833P 2020-09-15 2020-09-15
US63/078,833 2020-09-15
PCT/JP2021/033854 WO2022059691A1 (en) 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Publications (1)

Publication Number Publication Date
KR20230067646A true KR20230067646A (ko) 2023-05-16

Family

ID=80776688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012412A Pending KR20230067646A (ko) 2020-09-15 2021-09-15 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법

Country Status (6)

Country Link
US (1) US20230338342A1 (https=)
EP (1) EP4213841A4 (https=)
JP (1) JP2023541430A (https=)
KR (1) KR20230067646A (https=)
AU (1) AU2021344091A1 (https=)
WO (1) WO2022059691A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US20200405697A1 (en) * 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent

Also Published As

Publication number Publication date
EP4213841A1 (en) 2023-07-26
WO2022059691A1 (en) 2022-03-24
JP2023541430A (ja) 2023-10-02
US20230338342A1 (en) 2023-10-26
AU2021344091A9 (en) 2024-08-08
TW202227059A (zh) 2022-07-16
EP4213841A4 (en) 2024-07-24
AU2021344091A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
KR20230067646A (ko) 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법
JP7828333B2 (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
CN113038953B (zh) 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法
WO2025006697A1 (en) Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr
US20250049757A1 (en) Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
RU2859365C2 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
TWI914404B (zh) 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法
RU2848459C1 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
WO2026072904A2 (en) Compositions and methods for treating lung cancer
HK40129790A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40055650A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935A (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935B (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240829

Comment text: Request for Examination of Application